- Home
- ERC vs AVTX Comparison
ERC vs AVTX Comparison
Compare ERC & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERC
- AVTX
- Stock Information
- Founded
- ERC 2003
- AVTX 2011
- Country
- ERC United States
- AVTX United States
- Employees
- ERC N/A
- AVTX N/A
- Industry
- ERC Finance/Investors Services
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ERC Finance
- AVTX Health Care
- Exchange
- ERC Nasdaq
- AVTX Nasdaq
- Market Cap
- ERC 265.7M
- AVTX 248.3M
- IPO Year
- ERC N/A
- AVTX 2015
- Fundamental
- Price
- ERC $9.35
- AVTX $15.14
- Analyst Decision
- ERC
- AVTX Strong Buy
- Analyst Count
- ERC 0
- AVTX 9
- Target Price
- ERC N/A
- AVTX $30.14
- AVG Volume (30 Days)
- ERC 64.4K
- AVTX 412.1K
- Earning Date
- ERC 01-01-0001
- AVTX 11-06-2025
- Dividend Yield
- ERC 8.37%
- AVTX N/A
- EPS Growth
- ERC N/A
- AVTX N/A
- EPS
- ERC 0.72
- AVTX N/A
- Revenue
- ERC N/A
- AVTX $192,000.00
- Revenue This Year
- ERC N/A
- AVTX N/A
- Revenue Next Year
- ERC N/A
- AVTX N/A
- P/E Ratio
- ERC $12.92
- AVTX N/A
- Revenue Growth
- ERC N/A
- AVTX N/A
- 52 Week Low
- ERC $8.51
- AVTX $3.39
- 52 Week High
- ERC $9.74
- AVTX $19.41
- Technical
- Relative Strength Index (RSI)
- ERC 46.76
- AVTX 48.12
- Support Level
- ERC $9.33
- AVTX $14.16
- Resistance Level
- ERC $9.58
- AVTX $16.03
- Average True Range (ATR)
- ERC 0.09
- AVTX 1.27
- MACD
- ERC 0.01
- AVTX -0.42
- Stochastic Oscillator
- ERC 35.61
- AVTX 23.40
About ERC Allspring Multi-Sector Income Fund
Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).